Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H16ClF2N5O2 |
Molecular Weight | 431.823 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](N1C=NC2=CC(Cl)=CC=C2C1=O)[C@](O)(CN3C=NC=N3)C4=CC=C(F)C=C4F
InChI
InChIKey=UHIXWHUVLCAJQL-MPBGBICISA-N
InChI=1S/C20H16ClF2N5O2/c1-12(28-11-25-18-6-13(21)2-4-15(18)19(28)29)20(30,8-27-10-24-9-26-27)16-5-3-14(22)7-17(16)23/h2-7,9-12,30H,8H2,1H3/t12-,20-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20112166Curator's Comment: description was created based on several sources, including:
https://newdrugapprovals.org/2014/09/09/10613/ | http://adisinsight.springer.com/drugs/800009452
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20112166
Curator's Comment: description was created based on several sources, including:
https://newdrugapprovals.org/2014/09/09/10613/ | http://adisinsight.springer.com/drugs/800009452
Albaconazole is a triazole antifungal. Azoles are important antifungal compounds, and all drugs in this class inhibit ergosterol synthesis by blocking the 14-α-demethylase enzyme, resulting in the accumulation of toxic methylsterols that may culminate in fungal death. Albaconazole, an oral agent that has demonstrated high levels of bioavailability and potent antifungal activity. It was under development for the treatment of onychomycosis, vulvovaginal candidiasis. Also, albaconazole was evaluated in phase I, a randomized, placebo-controlled clinical trial in patients with tinea pedis. No serious adverse effects occurred in the studies involving albaconazole. However, this researches on this drug were discontinued.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1670 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23390369 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALBACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2350 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23390369 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALBACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
226 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23390369 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
6-HYDROXYALBACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
235 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23390369 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
6-HYDROXYALBACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
107796.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23390369 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALBACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
114472.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23390369 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALBACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
51216.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23390369 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
6-HYDROXYALBACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
53474.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23390369 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
6-HYDROXYALBACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
64.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23390369 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALBACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
57.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23390369 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALBACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
67.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23390369 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
6-HYDROXYALBACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
72.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23390369 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
6-HYDROXYALBACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
Other AEs: Dizziness, Aspartate aminotransferase increased... Other AEs: Dizziness (1%) Sources: Aspartate aminotransferase increased Nause (3%) Aspartate aminotransferase increased Constipation (1%) Blood creatine phosphokinase increase (4%) vomiting (1%) Diarrhea (3%) Aspartate aminotransferase increased (2%) Upper respiratory tract infection (3%) Blood glucose increased (2%) Alanine aminotransferase increase (3%) Abdominal discomfor (1%) Gastroenteritis (1%) Neutrophil count decrease (1%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Aspartate aminotransferase increased | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
|
Aspartate aminotransferase increased | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
|
Abdominal discomfor | 1% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
Constipation | 1% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
Dizziness | 1% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
Gastroenteritis | 1% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
Neutrophil count decrease | 1% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
vomiting | 1% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
Aspartate aminotransferase increased | 2% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
Blood glucose increased | 2% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
Alanine aminotransferase increase | 3% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
Diarrhea | 3% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
Nause | 3% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
Upper respiratory tract infection | 3% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
Blood creatine phosphokinase increase | 4% | 400 mg 1 times / week multiple, oral (unknown) Highest studied dose Dose: 400 mg, 1 times / week Route: oral Route: multiple Dose: 400 mg, 1 times / week Sources: |
unhealthy n = 116 Health Status: unhealthy Condition: distal subungual onychomycosis Sex: M+F Food Status: UNKNOWN Population Size: 116 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. | 1998 May 21 |
|
In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. | 1999 Aug |
|
Specific treatment of Chagas disease: current status and new developments. | 2001 Dec |
|
In vitro activities of four novel triazoles against Scedosporium spp. | 2001 Jul |
|
In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. | 2001 Sep |
|
In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. | 2004 Feb |
|
In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. | 2004 Jan |
|
Measurement of the sign and the magnitude of heteronuclear coupling constants from spin-state-edited J-cross-polarization NMR experiments. | 2004 Oct |
|
Emerging azole antifungals. | 2005 Feb |
|
Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. | 2005 Sep |
|
Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. | 2006 Dec |
|
Voriconazole in the management of nosocomial invasive fungal infections. | 2006 Jun |
|
Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. | 2006 Jun |
|
In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates. | 2006 May |
|
[Identification and susceptibility against fluconazole and albaconazole of 100 yeasts' strains isolated from vaginal discharge]. | 2007 Dec 31 |
|
New and investigational triazole agents for the treatment of invasive fungal infections. | 2008 Dec |
|
New and emerging treatments for fungal infections. | 2008 Jan |
|
Triazole derivatives with antifungal activity: a pharmacophore model study. | 2008 Nov-Dec |
|
Influence of Ecto-nucleoside triphosphate diphosphohydrolase activity on Trypanosoma cruzi infectivity and virulence. | 2009 |
|
New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. | 2009 Oct |
|
New generation azole antifungals in clinical investigation. | 2009 Sep |
|
Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections. | 2010 |
|
[Recent advances in the study of new antifungal lead compounds]. | 2010 Aug |
|
Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. | 2010 Feb |
|
Chromatographic and electrophoretic techniques used in the analysis of triazole antifungal agents-a review. | 2010 Sep 15 |
|
Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility. | 2014 May 8 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23706639
100, 200 and 400 mg weekly for 24 or 36 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10952601
The clinically relevant intracellular amastigote forms, proliferating in cultured Vero cells at 37°C, were more susceptible to Albaconazole than epimastigotes: the MIC required to reduce infected cells by 99% and the IC50 (concentration of the drug required to reduce infected cells by 50%) were in this case 10 nM and 1 nM, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ALBACONAZOLE
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
PRIMARY | |||
|
208952
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
PRIMARY | |||
|
8195
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
PRIMARY | |||
|
UU-31
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
PRIMARY | |||
|
DTXSID3058244
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
PRIMARY | |||
|
DB12073
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
PRIMARY | |||
|
C72952
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
PRIMARY | |||
|
187949-02-6
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
PRIMARY | |||
|
100000124470
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
PRIMARY | |||
|
SUB32139
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
PRIMARY | |||
|
YDW24Y8IAB
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
PRIMARY | |||
|
CHEMBL298817
Created by
admin on Fri Dec 15 16:19:25 GMT 2023 , Edited by admin on Fri Dec 15 16:19:25 GMT 2023
|
PRIMARY |
ACTIVE MOIETY